NEW YORK (GenomeWeb) – Meridian Bioscience today reported a slight improvement in its fiscal third quarter sales as it missed consensus Wall Street expectations on the top and bottom lines.

The Cincinnati-based firm said that for the three months ended June 30, sales inched up to $47.2 million, an increase of a fraction of 1 percent from $47.1 million during its fiscal year 2013 third quarter and below the average analyst estimate of $48 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.